Collegium Pharmaceutical, INC: directors' dealings · United States · SEC (Form 4)

About Collegium Pharmaceutical, INC

Collegium Pharmaceutical, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq Global Market under the ticker COLL. The company is headquartered in Stoughton, Massachusetts, and completed its initial public offering in May 2015. Collegium has built its business around specialty medicines for serious medical conditions, initially focused on chronic pain and more recently expanded into neuropsychiatry. ([ir.collegiumpharma.com](https://ir.collegiumpharma.com/investor-resources/investor-faqs)) From a historical perspective, Collegium first established its commercial footprint in the pain-management category with differentiated, prescription-based therapies. Its core products include Xtampza ER, an extended-release opioid analgesic, alongside Nucynta IR and Nucynta ER, which remain important contributors to the company’s portfolio. In September 2024, Collegium acquired Ironshore Therapeutics, adding Jornay PM, a treatment for attention-deficit hyperactivity disorder, and thereby broadening the company beyond its traditional pain franchise into ADHD and neuropsychiatry. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267565/000155837025003983/coll-20250515xdef14a.htm)) Competitively, Collegium is best viewed as a focused specialty pharma company rather than a broad, multi-franchise large-cap peer. Its strategy emphasizes commercial execution, lifecycle management of marketed brands, and disciplined capital allocation. This model has supported meaningful cash generation while the company continues to diversify its revenue base. In 2025, Collegium reported net product revenues of $780.6 million, up from $631.4 million in 2024, underscoring the strength of its commercial platform and the contribution of newer assets. ([ir.collegiumpharma.com](https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-fourth-quarter-and-full-year-2025-financial)) Geographically, the company’s commercial and regulatory focus is overwhelmingly the United States. That matters because Collegium’s performance is closely tied to U.S. prescribing trends, payer dynamics, regulatory scrutiny, and patent/exclusivity outcomes. Management has highlighted a six-month extension of U.S. pediatric exclusivity for certain Nucynta products, improving the near-term value proposition of that franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267565/000155837025003983/coll-20250515xdef14a.htm)) Recent developments have been centered on revenue growth, operating cash flow, capital deployment, and portfolio optimization. Collegium has also been active on financing and balance-sheet management, while continuing to disclose litigation and regulatory risks associated with specialty pain medicines. For investors in Europe looking at a U.S.-listed healthcare name, Collegium represents a niche, cash-generative specialty pharma platform with improving diversification, but one that still carries the typical risks of the U.S. pain market and a concentrated product portfolio. ([ir.collegiumpharma.com](https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-fourth-quarter-and-full-year-2025-financial))